Pekin Hardy Strauss Inc. lifted its position in Johnson & Johnson (NYSE:JNJ) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,143 shares of the company’s stock after acquiring an additional 100 shares during the quarter. Johnson & Johnson accounts for approximately 1.1% of Pekin Hardy Strauss Inc.’s investment portfolio, making the stock its 29th largest holding. Pekin Hardy Strauss Inc.’s holdings in Johnson & Johnson were worth $5,173,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC grew its stake in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the last quarter. Permanens Capital L.P. grew its stake in Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares during the last quarter. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. Thor Advisors LLC purchased a new position in Johnson & Johnson in the first quarter valued at about $69,000. Finally, Personal Wealth Partners purchased a new position in Johnson & Johnson in the second quarter valued at about $73,000. Hedge funds and other institutional investors own 72.12% of the company’s stock.
Shares of JNJ stock traded down $0.32 during trading hours on Friday, reaching $130.11. 1,656,706 shares of the company’s stock were exchanged, compared to its average volume of 7,701,360. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The stock has a market cap of $341.90 billion, a PE ratio of 15.91, a PEG ratio of 2.19 and a beta of 0.68. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The stock’s fifty day moving average price is $130.11 and its two-hundred day moving average price is $135.97.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the firm earned $2.10 earnings per share. The company’s revenue was down 1.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s payout ratio is 46.45%.
JNJ has been the topic of several analyst reports. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Raymond James dropped their price target on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a research note on Thursday, July 18th. Finally, Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $150.60.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: The Structure of a Futures Contract
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.